ESTRO 2024 - Abstract Book

S2004

Clinical - Mixed sites, palliation

ESTRO 2024

Al-Shafa, F., Arifin, A. J., Rodrigues, G. B., Palma, D. A. and Louie, A., V. (2019) A review of ongoing trials of stereotactic ablative radiotherapy for oligometastatic cancers: Where will the evidence lead? Frontiers in Oncology, 9 , pp. 543. DOI: 10.3389/fonc.2019.00543. Palma, D. A., Olson, R., Harrow, S., Gaede, S., Louie, A. V., Haasbeek, C., Mulroy, L., Lock, M., Rodrigues, G. B., Yaremko, B. P., Schellenberg, D., Ahmad, B., Griffioen, G., Senthi, S., Swaminath, A., Kopek, N., Liu, M., Moore, K., Currie, S., Bauman, G. S., Warner, A. and Senan, S. (2019) Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): A randomised, phase 2, open-label trial, The Lancet, 393 (10185), pp. 2051-2058. DOI: 10.1016/S0140-6736(18)32487-5. Pignon, J., Maître, A. l., Maillard, E. and Bourhis, J. (2009) Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients, Radiotherapy and Oncology, 92 (1), pp. 4-14. DOI: 10.1016/j.radonc.2009.04.014.

3017

Proffered Paper

SABR of bony oligometastases, 1-year efficacy, and toxicity analyses from the Bony-M trial

Nicklas J Spindler 1 , Mette v O Felter 1 , Olfred Hansen 2,3 , Tine B Nielsen 2 , Morten H Suppli 4 , Mirjana Josipovic 4 , Laurids Ø Poulsen 5 , Fatma Gaard-Petersen 1 , Michael B Andersen 6,7 , Hella M B Sand 5 , Marie Johansen 8 , Kasper Madsen 1 , Josefine S Kornerup 9 , Mirjam D Alsaker 9 , Eva Serup-Hansen 1 , Rikke L Eefsen 1 , Ivan R Vogelius 4,7 , Poul Geertsen 1 , Claus P Behrens 1 , Gitte F Persson 1,7 1 Copenhagen University Hospital - Herlev and Gentofte, Department of Oncology, Herlev, Denmark. 2 Odense University Hospital, Department of Oncology, Odense, Denmark. 3 University of Southern Denmark, Department of Clinical Research, Odense, Denmark. 4 Copenhagen University Hospital - Rigshospitalet, Department of Oncology, Copenhagen, Denmark. 5 Aalborg University Hospital, Department of Oncology, Aalborg, Denmark. 6 Copenhagen University Hospital - Herlev and Gentofte, Department of Radiology, Herlev, Denmark. 7 University of Copenhagen, Faculty of Health, Department of Clinical Medicine, Copenhagen, Denmark. 8 Ålesund Hospital, Department of Radiotherapy, Ålesund, Norway. 9 St Olavs University hospital, Department of Radiotherapy, Trondheim, Norway

Purpose/Objective:

Stereotactic ablative radiotherapy (SABR) is increasingly applied to control oligometastatic disease (OMD). As patients may be asymptomatic, severe treatment-related toxicity (TRAE) is unacceptable in this setting.

The Bony-M trial (SABR of Bony Metastases in patients with OMD) evaluates the efficacy and toxicity of risk-adapted SABR to bony metastases (Clinicaltrails.gov: NCT05101824). We present the 1-year analyses of local control, TRAEs, fractures, and pain response.

Material/Methods: